Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2023 | Thyroid Cancer | Research

Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells

Authors: Le-Tian Huang, Tie-Jun Li, Ming-Lin Li, Han-Yong Luo, Yi-Bing Wang, Jia-He Wang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Abstract

Background

With fast rising incidence, papillary thyroid carcinoma (PTC) is the most common head and neck cancer. Parthenolide, isolated from traditional Chinese medicine, inhibits various cancer cells, including PTC cells. The aim was to investigate the lipid profile and lipid changes of PTC cells when treated with parthenolide.

Methods

Comprehensive lipidomic analysis of parthenolide treated PTC cells was conducted using a UHPLC/Q-TOF–MS platform, and the changed lipid profile and specific altered lipid species were explored. Network pharmacology and molecular docking were performed to show the associations among parthenolide, changed lipid species, and potential target genes.

Results

With high stability and reproducibility, a total of 34 lipid classes and 1736 lipid species were identified. Lipid class analysis indicated that parthenolide treated PTC cells contained higher levels of fatty acid (FA), cholesterol ester (ChE), simple glc series 3 (CerG3) and lysophosphatidylglycerol (LPG), lower levels of zymosterol (ZyE) and Monogalactosyldiacylglycerol (MGDG) than controlled ones, but with no significant differences. Several specific lipid species were changed significantly in PTC cells treated by parthenolide, including the increasing of phosphatidylcholine (PC) (12:0e/16:0), PC (18:0/20:4), CerG3 (d18:1/24:1), lysophosphatidylethanolamine (LPE) (18:0), phosphatidylinositol (PI) (19:0/20:4), lysophosphatidylcholine (LPC) (28:0), ChE (22:6), and the decreasing of phosphatidylethanolamine (PE) (16:1/17:0), PC (34:1) and PC (16:0p/18:0). Four key targets (PLA2G4A, LCAT, LRAT, and PLA2G2A) were discovered when combining network pharmacology and lipidomics. Among them, PLA2G2A and PLA2G4A were able to bind with parthenolide confirmed by molecular docking.

Conclusions

The changed lipid profile and several significantly altered lipid species of parthenolide treated PTC cells were observed. These altered lipid species, such as PC (34:1), and PC (16:0p/18:0), may be involved in the antitumor mechanisms of parthenolide. PLA2G2A and PLA2G4A may play key roles when parthenolide treated PTC cells.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef

Wang X, Lu X, Geng Z, Yang G, Shi Y. LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via Wnt/β-Catenin signaling. J Cell Biochem. 2017;118(12):4745–52.PubMedCrossRef

Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22(6):395–404.PubMedCrossRef

Gao W, Li L, Zhang X, et al. Nanomagnetic liposome-encapsulated parthenolide and indocyanine green for targeting and chemo-photothermal antitumor therapy. Nanomedicine (Lond). 2020;15(9):871–90.PubMedCrossRef

Yuan L, Wang Z, Zhang D, Wang J. Metabonomic study of the intervention effects of Parthenolide on anti-thyroid cancer activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1150: 122179.PubMedCrossRef

Talib WH, Al Kury LT. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. Biomed Pharmacother. 2018;107:1488–95.PubMedCrossRef

Ge W, Hao X, Han F, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445–69.PubMedCrossRef

Li X, Kong L, Yang Q, et al. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. J Biol Chem. 2020;295(11):3576–89.PubMedPubMedCentralCrossRef

Liu M, Xiao C, Sun M, Tan M, Hu L, Yu Q. Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases. Molecules. 2018;23(6):1478.PubMedPubMedCentralCrossRef

10.

Kim SL, Park YR, Lee ST, Kim SW. Parthenolide suppresses hypoxia-inducible factor-1α signaling and hypoxia induced epithelial-mesenchymal transition in colorectal cancer. Int J Oncol. 2017;51(6):1809–20.PubMedCrossRef

11.

Gao W, Wei S, Li Z, et al. Nano magnetic liposomes-encapsulated parthenolide and glucose oxidase for ultra-efficient synergistic antitumor therapy. Nanotechnology. 2020;31(35): 355104.PubMedCrossRef

12.

Carlisi D, Lauricella M, D’Anneo A, et al. Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties. Biomedicines. 2022;10(2):514.PubMedPubMedCentralCrossRef

13.

Cui M, Wang Z, Huang LT, Wang JH. Parthenolide leads to proteomic differences in thyroid cancer cells and promotes apoptosis. BMC Complement Med Ther. 2022;22(1):99.PubMedPubMedCentralCrossRef

14.

Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 2002;62(21):6329–36.PubMed

15.

Ishikawa S, Tateya I, Hayasaka T, et al. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS ONE. 2012;7(11):e48873.PubMedPubMedCentralCrossRef

16.

Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279(15):2610–23.PubMedCrossRef

17.

Antal O, Péter M, Hackler L Jr, et al. Lipidomic analysis reveals a radiosensitizing role of gamma-linolenic acid in glioma cells. Biochim Biophys Acta. 2015;1851(9):1271–82.PubMedCrossRef

18.

Jiang N, Zhang Z, Chen X, et al. Plasma Lipidomics Profiling Reveals Biomarkers for Papillary Thyroid Cancer Diagnosis. Front Cell Dev Biol. 2021;9:682269.PubMedPubMedCentralCrossRef

19.

Cheng F, Wen Z, Feng X, Wang X, Chen Y. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer. Life Sci. 2020;260: 118489.PubMedCrossRef

20.

Bedia C, Dalmau N, Jaumot J, Tauler R. Phenotypic malignant changes and untargeted lipidomic analysis of long-term exposed prostate cancer cells to endocrine disruptors. Environ Res. 2015;140:18–31.PubMedCrossRef

21.

Li Y, Li Y, Lu W, et al. Integrated Network Pharmacology and Metabolomics Analysis of the Therapeutic Effects of Zi Dian Fang on Immune Thrombocytopenic Purpura. Front Pharmacol. 2018;9:597.PubMedPubMedCentralCrossRef

22.

Pang HQ, Yue SJ, Tang YP, et al. Integrated Metabolomics and Network Pharmacology Approach to Explain Possible Action Mechanisms of Xin-Sheng-Hua Granule for Treating Anemia. Front Pharmacol. 2018;9:165.PubMedPubMedCentralCrossRef

23.

Zeng Q, Li L, Jin Y, et al. A network pharmacology approach to reveal the underlying mechanisms of Paeonia lactiflora Pall. On the treatment of alzheimer’s disease. Evid Based Complement Alternat Med. 2019;2019:8706589.PubMedPubMedCentralCrossRef

24.

Ingram LM, Finnerty MC, Mansoura M, Chou CW, Cummings BS. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells. Lipids Health Dis. 2021;20(1):15.PubMedPubMedCentralCrossRef

25.

Lu J, Zhang Y, Sun M, et al. Multi-omics analysis of fatty acid metabolism in thyroid carcinoma. Front Oncol. 2021;11:737127.PubMedPubMedCentralCrossRef

26.

Wen S, Luo Y, Wu W, et al. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer. Acta Biochim Biophys Sin (Shanghai). 2021;53(12):1579–89.PubMedCrossRef

27.

Wang R, Zhao H, Zhang X, Zhao X, Song Z, Ouyang J. Metabolic discrimination of breast cancer subtypes at the single-cell level by multiple microextraction coupled with mass spectrometry. Anal Chem. 2019;91(5):3667–74.PubMedCrossRef

28.

Guo S, Wang Y, Zhou D, Li Z. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci Rep. 2014;4:5959.PubMedPubMedCentralCrossRef

29.

Guo Y, Ren J, Li X, et al. Simultaneous quantification of serum multi-phospholipids as potential biomarkers for differentiating different pathophysiological states of lung, stomach, intestine, and pancreas. J Cancer. 2017;8(12):2191–204.PubMedPubMedCentralCrossRef

30.

Uchiyama Y, Hayasaka T, Masaki N, et al. Imaging mass spectrometry distinguished the cancer and stromal regions of oral squamous cell carcinoma by visualizing phosphatidylcholine (16:0/16:1) and phosphatidylcholine (18:1/20:4). Anal Bioanal Chem. 2014;406(5):1307–16.PubMedCrossRef

31.

Jiang N, Zhang G, Pan L, et al. Potential plasma lipid biomarkers in early-stage breast cancer. Biotechnol Lett. 2017;39(11):1657–66.PubMedCrossRef

32.

Wojakowska A, Cole LM, Chekan M, et al. Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging. Endokrynol Pol. 2018;69(1):2–8.PubMedCrossRef

33.

Guo S, Qiu L, Wang Y, et al. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal Bioanal Chem. 2014;406(18):4357–70.PubMedCrossRef

34.

Lee GB, Lee JC, Moon MH. Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2019;1063:117–26.PubMedCrossRef

35.

Benesch MG, Ko YM, Tang X, et al. Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. Endocr Relat Cancer. 2015;22(4):593–607.PubMedCrossRef

36.

Foldbjerg R, Dang DA, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2011;85(7):743–50.PubMedCrossRef

37.

Kasurinen S, Jalava PI, Happo MS, et al. Particulate emissions from the combustion of birch, beech, and spruce logs cause different cytotoxic responses in A549 cells. Environ Toxicol. 2017;32(5):1487–99.PubMedCrossRef

38.

Zhao R, Lv Y, Feng T, et al. ATF6α promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis. Prostate. 2022;82(5):617–29.PubMedPubMedCentralCrossRef

39.

Zhan Y, Zheng L, Liu J, et al. PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization. JCI Insight. 2021;6(16):e148028.PubMedPubMedCentralCrossRef

40.

Hatori S, Sakamaki K, Yokohori T, et al. Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1. Anticancer Res. 2021;41(7):3583–8.PubMedCrossRef

41.

Ozturk K, Onal MS, Efiloglu O, Nikerel E, Yildirim A, Telci D. Association of 5’UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis. Gene. 2020;742: 144589.PubMedCrossRef

42.

Sharma P, Levesque T, Boilard E, Park EA. Thyroid hormone status regulates the expression of secretory phospholipases. Biochem Biophys Res Commun. 2014;444(1):56–62.PubMedPubMedCentralCrossRef

43.

Sharma P, Thakran S, Deng X, Elam MB, Park EA. Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone. J Biol Chem. 2013;288(23):16321–33.PubMedPubMedCentralCrossRef

Title: Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
Authors: Le-Tian Huang
Tie-Jun Li
Ming-Lin Li
Han-Yong Luo
Yi-Bing Wang
Jia-He Wang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-023-03944-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Correction: Effects of Vitellaria paradoxa (C.F. Gaertn.) Aqueous leaf extract administration on Salmonella typhimurium-infected rats

Assessment of antimicrobial and anthelmintic activity of silver nanoparticles bio-synthesized from Viscum orientale leaf extract

Inhibitory effect of O-propargyllawsone in A549 lung adenocarcinoma cells

Patient-shared knowledge and information in clinical decision-making: an international survey of the perspectives and experiences of naturopathic practitioners

In utero and postnatal exposure to Foeniculum vulgare and Linum usitatissimum seed extracts: modifications of key enzymes involved in epigenetic regulation and estrogen receptors expression in the offspring’s ovaries of NMRI mice

Analysis of the potential biological mechanisms of Danyu Gukang Pill against osteonecrosis of the femoral head based on network pharmacology